Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1921 1
1947 2
1948 2
1949 2
1950 1
1951 1
1952 1
1954 6
1955 5
1956 1
1957 2
1958 5
1959 3
1961 2
1962 1
1963 4
1964 7
1965 4
1966 4
1967 4
1968 10
1969 5
1970 9
1971 9
1972 6
1973 10
1974 12
1975 30
1976 33
1977 38
1978 28
1979 62
1980 98
1981 91
1982 86
1983 106
1984 131
1985 145
1986 131
1987 160
1988 148
1989 176
1990 140
1991 176
1992 191
1993 199
1994 212
1995 197
1996 229
1997 257
1998 221
1999 220
2000 230
2001 257
2002 217
2003 283
2004 253
2005 283
2006 255
2007 299
2008 280
2009 277
2010 298
2011 350
2012 349
2013 326
2014 351
2015 343
2016 369
2017 312
2018 329
2019 336
2020 368
2021 346
2022 283
2023 276
2024 285
2025 297
2026 149

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,792 results

Results by year

Filters applied: . Clear all
Page 1
Prostate Cancer: A Review.
Raychaudhuri R, Lin DW, Montgomery RB. Raychaudhuri R, et al. JAMA. 2025 Apr 22;333(16):1433-1446. doi: 10.1001/jama.2025.0228. JAMA. 2025. PMID: 40063046 Review.
For patients with newly diagnosed metastatic prostate cancer, the addition of androgen receptor pathway inhibitors (eg, darolutamide, abiraterone) improves survival. ...Approximately 10% of patients present with metastatic prostate cancer, which has a …
For patients with newly diagnosed metastatic prostate cancer, the addition of androgen receptor pathway inhibitors (eg, darolu …
A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease.
Trinh JQ, Lele SM, Teply BA. Trinh JQ, et al. Prostate. 2023 Jun;83(8):814-819. doi: 10.1002/pros.24521. Epub 2023 Mar 26. Prostate. 2023. PMID: 36967482 Review.
BACKGROUND: Metastatic adenoid cystic (basal cell) carcinoma of the prostate is an exceedingly rare disease entity. As a result, no current consensus exists for optimal systemic therapy. METHODS: We present a patient with metastatic adenoid cystic (bas …
BACKGROUND: Metastatic adenoid cystic (basal cell) carcinoma of the prostate is an exceedingly rare disease entity. As …
Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patients.
Wei X, Zhao J, Nie L, Shi Y, Zhao F, Shen Y, Chen J, Sun G, Zhang X, Liang J, Hu X, Shen P, Chen N, Zeng H, Liu Z. Wei X, et al. Prostate. 2025 Feb;85(2):130-139. doi: 10.1002/pros.24809. Epub 2024 Oct 28. Prostate. 2025. PMID: 39465570 Free PMC article.
BACKGROUND: This study explored the value of intraductal carcinoma of the prostate (IDC-P) in predicting the efficacy of abiraterone treatment in metastatic hormone-sensitive prostate cancer (mHSPC) patients. METHODS: A retrospective study of 925 patie …
BACKGROUND: This study explored the value of intraductal carcinoma of the prostate (IDC-P) in predicting the efficacy of abira …
Expression of HER2/NEU in newly diagnosed metastatic carcinoma prostate on TRUS biopsy specimen and its clinical correlation and progression.
Abhishek A, Sarkar D, Kumar Pal D. Abhishek A, et al. Urologia. 2023 May;90(2):244-247. doi: 10.1177/03915603221118471. Epub 2022 Aug 24. Urologia. 2023. PMID: 36000702
Overexpression of the Her2/neu receptor tyrosine kinase has been associated with the progression to androgen independence in prostate cancer cells. OBJECTIVE: Our primary aim was to investigate the frequency of HER2/neu amplification in prostate biopsy specimens in …
Overexpression of the Her2/neu receptor tyrosine kinase has been associated with the progression to androgen independence in prostate …
Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
Naito Y, Kato M, Kawanishi H, Yamamoto A, Sakamoto F, Hirabayashi H, Kobayashi M, Matsukawa Y, Kimura T, Araki H, Nishikimi T, Kondo A, Yoshino Y, Hashimoto Y, Nakano Y, Tsuzuki T. Naito Y, et al. Prostate. 2023 Mar;83(4):307-315. doi: 10.1002/pros.24462. Epub 2022 Nov 24. Prostate. 2023. PMID: 36420892
BACKGROUND: In recent years, the usefulness of androgen receptor axis-targeted agents (ARATs) such as abiraterone, enzalutamide, and apalutamide for the upfront treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been demonstrated. However, it rema …
BACKGROUND: In recent years, the usefulness of androgen receptor axis-targeted agents (ARATs) such as abiraterone, enzalutamide, and apaluta …
(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Mokoala K, Reed J, Maseremule L, Ndlovu H, Hlongwa K, Maes A, Morgenstern A, Van de Wiele C. Sathekge M, et al. Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2210-2218. doi: 10.1007/s00259-023-06165-9. Epub 2023 Mar 3. Eur J Nucl Med Mol Imaging. 2023. PMID: 36864360 Free PMC article.
PURPOSE: (225)Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients. No study has previously assessed treatment outcome and survival following (225)Ac-PSMA-617 treatment of de n …
PURPOSE: (225)Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant prosta …
Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
Naito Y, Kato M, Nagayama J, Sano Y, Matsuo K, Inoue S, Sano T, Ishida S, Matsukawa Y, Tsuzuki T, Akamatsu S. Naito Y, et al. Int J Urol. 2024 Jan;31(1):7-16. doi: 10.1111/iju.15299. Epub 2023 Sep 20. Int J Urol. 2024. PMID: 37728330 Review.
Intraductal carcinoma of the prostate is almost invariably associated with an adjacent high-grade carcinoma and is occasionally observed as an isolated subtype. Intraductal carcinoma of the prostate has been demonstrated to be an independent poo …
Intraductal carcinoma of the prostate is almost invariably associated with an adjacent high-grade carcinoma and is occa …
Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes.
Bilé-Silva A, Lopez-Beltran A, Rasteiro H, Vau N, Blanca A, Gomez E, Gaspar F, Cheng L. Bilé-Silva A, et al. Virchows Arch. 2023 Mar;482(3):493-505. doi: 10.1007/s00428-022-03481-7. Epub 2023 Jan 5. Virchows Arch. 2023. PMID: 36600115 Free PMC article.
We report on the clinicopathologic features of 27 pleomorphic giant cell carcinoma (PGCC) cases of the prostate identified in 20 patients with an age range of 51 to 84 years (68 9; median 71 years). ...Our findings suggest that PGCC is a rare and aggressive subtyp …
We report on the clinicopathologic features of 27 pleomorphic giant cell carcinoma (PGCC) cases of the prostate identified in …
Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications.
Tariq A, McCart Reed AE, Morton A, Porten S, Vela I, Williams ED, Yaxley JW, Black PC, Roberts MJ. Tariq A, et al. Eur Urol Focus. 2022 Sep;8(5):1256-1269. doi: 10.1016/j.euf.2021.07.016. Epub 2021 Aug 21. Eur Urol Focus. 2022. PMID: 34429271
CONTEXT: Staging, restaging, and surveillance of urothelial carcinoma (UC) is challenging due to suboptimal accuracy of standard of care imaging modalities. Prostate-specific membrane antigen (PSMA) imaging may serve to improve characterisation of UC. ...
CONTEXT: Staging, restaging, and surveillance of urothelial carcinoma (UC) is challenging due to suboptimal accuracy of standard of c …
Neuroendocrine carcinoma of prostate presenting with ascites.
Sagar N, Kushwaha P, Mallya V, Jain S, Khurana N, Hadke NS. Sagar N, et al. J Cancer Res Ther. 2021 Apr-Jun;17(2):577-579. doi: 10.4103/jcrt.JCRT_772_17. J Cancer Res Ther. 2021. PMID: 34121712 Free article.
Prostate cancer is a very common cause of morbidity and mortality in India. The commonest type of prostate carcinoma is adenocarcinoma, most of them are confined to prostate at the time of presentation. ...A TRUS guided biopsy showed neuroendocrine …
Prostate cancer is a very common cause of morbidity and mortality in India. The commonest type of prostate carcinoma is …
10,792 results
You have reached the last available page of results. Please see the User Guide for more information.